IN8bio, Inc. (INAB)
INAB moved a median of -0.52% 30 minutes after news, and -1.85% by the close. How INAB actually reacts to news — the realized, point-in-time move the market made, measured across 287 labeled events over the last three years with zero look-ahead.
INAB’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 44% | 271 |
| 30-min | -0.52% | 39% | 286 |
| 60-min | -1.18% | 35% | 287 |
| to close | -1.85% | 31% | 286 |
| Middle 50% of INAB reactions | -2.38% to +1.46% |
|---|---|
| Median reaction (30-min) | -0.52% |
| Measured reactions | 287 |
Half of all IN8bio, Inc. news events land between -2.38% and +1.46% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when INAB moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to INAB's baseline. Nothing else.
Recent INAB events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | — | +1.45% | |
| IN8bio to Present at Sidoti Small-Cap Virtual Conference | Press release | GlobeNewswire | +0.00% | -4.35% | |
| IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference | Press release | GlobeNewswire | +0.00% | +1.85% | |
| IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development | Press release | GlobeNewswire | +0.19% | -1.82% | |
| Form S-8 IN8BIO, INC. | SEC filing · Form S-8 | SEC EDGAR | — | +1.05% | |
| Form 10-Q IN8BIO, INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | — | +1.05% | |
| Form 8-K IN8BIO, INC. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | — | +1.05% | |
| IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights | Press release | GlobeNewswire | — | +1.05% | |
| IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma | Press release | GlobeNewswire | +3.60% | +0.72% | |
| IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies | Press release | GlobeNewswire | -0.64% | -1.28% | |
| Form 8-K IN8BIO, INC. For: May 29 | SEC filing · Form 8-K | SEC EDGAR | -1.09% | -5.98% | |
| IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026 | Press release | GlobeNewswire | -1.09% | -5.98% | |
| Form EFFECT IN8BIO, INC. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +8.28% | |
| Form S-3/A IN8BIO, INC. | SEC filing · Form S-3 | SEC EDGAR | — | +2.84% | |
| IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma | Press release | GlobeNewswire | +0.00% | -3.64% | |
| Form 10-Q IN8BIO, INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.34% | -4.82% | |
| Form 8-K IN8BIO, INC. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -2.34% | -4.82% | |
| Form S-8 IN8BIO, INC. | SEC filing · Form S-8 | SEC EDGAR | -2.34% | -4.82% | |
| Form S-8 POS IN8BIO, INC. | SEC filing · Form S-8 | SEC EDGAR | -2.34% | -4.82% | |
| IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights | Press release | GlobeNewswire | -2.34% | -4.82% | |
| IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences | Press release | GlobeNewswire | +4.64% | +4.64% | |
| RedChip's Biotech Virtual Investor Conference Replays Now Available | Press release | ACCESS Newswire | — | -0.67% | |
| IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.00% | -2.76% | |
| Form ARS IN8BIO, INC. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.68% | -4.73% | |
| Form DEF 14A IN8BIO, INC. For: May 07 | SEC filing · Form DEF | SEC EDGAR | -0.68% | -4.73% | |
| Form DEFA14A IN8BIO, INC. | SEC filing · Form DEFA14A | SEC EDGAR | -0.68% | -4.73% | |
| Form 10-K IN8BIO, INC. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -9.00% | -5.50% | |
| Form 8-K IN8BIO, INC. For: Mar 12 | SEC filing · Form 8-K | SEC EDGAR | -9.00% | -5.50% | |
| IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026 | Press release | GlobeNewswire | -9.00% | -5.50% | |
| Form 8-K IN8BIO, INC. For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | — | |
| IN8bio to Present at TD Cowen 46th Annual Health Care Conference | Press release | GlobeNewswire | -1.31% | +1.31% | |
| Form 8-K IN8BIO, INC. For: Feb 04 | SEC filing · Form 8-K | SEC EDGAR | +4.59% | +2.04% | |
| IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer | Press release | GlobeNewswire | +4.59% | +2.04% | |
| IN8bio to Present at Upcoming Investor and Scientific Conferences in February | Press release | GlobeNewswire | +3.57% | +1.53% | |
| Form EFFECT IN8BIO, INC. | SEC filing · Form EFFECT | SEC EDGAR | -0.51% | +2.04% | |
| Form S-3 IN8BIO, INC. | SEC filing · Form S-3 | SEC EDGAR | +3.59% | -1.69% | |
| IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma | Press release | GlobeNewswire | -3.85% | -6.84% | |
| Form D IN8BIO, INC. | SEC filing · Form D | SEC EDGAR | +0.22% | +1.30% | |
| Form 8-K IN8BIO, INC. For: Dec 18 | SEC filing · Form 8-K | SEC EDGAR | -0.64% | +28.10% | |
| IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager | Press release | GlobeNewswire | -4.10% | -17.12% | |
| Form 8-K IN8BIO, INC. For: Nov 21 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +8.89% | |
| Form S-3 IN8BIO, INC. | SEC filing · Form S-3 | SEC EDGAR | -0.62% | +6.83% | |
| Form 10-Q IN8BIO, INC. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +5.31% | -3.13% | |
| Form 8-K IN8BIO, INC. For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | +5.31% | -3.13% | |
| IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Press release | GlobeNewswire | +5.31% | -3.13% | |
| IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site | Press release | GlobeNewswire | +0.48% | -3.85% | |
| Form 8-K IN8BIO, INC. For: Oct 27 | SEC filing · Form 8-K | SEC EDGAR | -1.89% | -0.94% | |
| IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications | Press release | GlobeNewswire | -1.89% | -0.94% | |
| Form 10-Q IN8BIO, INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.72% | +7.44% | |
| Form 8-K IN8BIO, INC. For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | +3.72% | +7.44% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the INAB section they belong to.
Where else INAB is measured.
INAB earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is IN8bio, Inc.'s median reaction calculated?
Every labeled INAB news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 287 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 39% of INAB's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does INAB's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.